Schonfeld reports 5.33% stake in Inhibrx Biosciences

Inhibrx Biosciences, Inc. received a large shareholder disclosure from Schonfeld Strategic Advisors LLC, a Delaware limited liability company and investment adviser to several private funds and separately managed accounts.

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. received a large shareholder disclosure from Schonfeld Strategic Advisors LLC, a Delaware limited liability company and investment adviser to several private funds and separately managed accounts. Schonfeld reports beneficial ownership of 781,678 shares of Inhibrx Biosciences common stock, representing 5.33% of the outstanding class. This percentage is based on 14,671,186 shares outstanding as of May 8, 2026, as reported in Inhibrx Biosciences’ quarterly report for the period ended March 31, 2026. Schonfeld has sole voting and dispositive power over these 781,678 shares, while its clients, on whose behalf the securities are held, have the right to receive dividends and sale proceeds. Schonfeld states that the filing should not be construed as an admission that it is the beneficial owner of these securities for any legal purpose.

Key Figures

Shares beneficially owned: 781,678 shares Percent of class owned: 5.33% Shares outstanding baseline: 14,671,186 shares +3 more

6 metrics

Shares beneficially owned 781,678 shares Common stock of Inhibrx Biosciences reported by Schonfeld Strategic Advisors LLC

Percent of class owned 5.33% Portion of Inhibrx Biosciences common stock class reported as beneficially owned

Shares outstanding baseline 14,671,186 shares Inhibrx Biosciences common stock outstanding as of May 8, 2026

Sole voting power 781,678 shares Shares over which Schonfeld has sole power to vote or direct the vote

Sole dispositive power 781,678 shares Shares over which Schonfeld has sole power to dispose or direct disposition

Signature date 08/14/2026 Date signed by Hung Luc, Chief Compliance Officer

Key Terms

beneficially own, sole voting power, sole dispositive power, separately managed accounts, +1 more

5 terms

beneficially own financial

"Schonfeld may be deemed to indirectly beneficially own securities owned by the Schonfeld SMAs."

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole voting power financial

"Sole Voting Power 781,678.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power 781,678.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

separately managed accounts financial

"assets of its private funds as separately managed accounts (the "Schonfeld SMAs")."

A separately managed account is an investment portfolio owned by a single investor but professionally managed to that investor’s specific goals and preferences, rather than pooled with other clients’ money. It matters to investors because it offers greater customization, tax control and transparency—like hiring a personal chef instead of eating from a shared buffet—though it often requires higher minimums and can have different fee and liquidity implications.

percent of class financial

"Percent of class: 5.33%"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Inhibrx Biosciences (INBX) shares does Schonfeld Strategic Advisors LLC report owning?

Schonfeld Strategic Advisors LLC reports beneficial ownership of 5.33% of Inhibrx Biosciences’ common stock, representing 781,678 shares. This is calculated using 14,671,186 shares outstanding as of May 8, 2026, cited from Inhibrx Biosciences’ Form 10-Q.

How many Inhibrx Biosciences (INBX) shares does Schonfeld Strategic Advisors LLC control?

Schonfeld Strategic Advisors LLC reports beneficial ownership of 781,678 shares of Inhibrx Biosciences common stock. It has sole voting power and sole dispositive power over all 781,678 shares, with no shared voting or dispositive power reported.

On what share count is Schonfeld’s 5.33% stake in Inhibrx Biosciences (INBX) based?

The reported 5.33% ownership is based on 14,671,186 shares of Inhibrx Biosciences common stock outstanding as of May 8, 2026, as set forth in the company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026.

Who ultimately benefits from the Inhibrx Biosciences (INBX) shares managed by Schonfeld Strategic Advisors LLC?

The Inhibrx Biosciences shares are held in accounts managed by Schonfeld for its clients. Those clients have the right to receive, or direct the receipt of, dividends and sale proceeds from the securities held by the separately managed accounts.

Does Schonfeld Strategic Advisors LLC admit full beneficial ownership of its Inhibrx Biosciences (INBX) position?

Schonfeld states that nothing in the statement should be construed as an admission of beneficial ownership for purposes of Section 13(d), Section 13(g), or any other legal purpose, despite reporting voting and dispositive power over the shares.

What type of securities in Inhibrx Biosciences (INBX) are covered by Schonfeld’s 13G filing?

The filing covers Inhibrx Biosciences’ Common Stock, par value $0.0001 per share. Schonfeld reports 781,678 shares of this class, corresponding to 5.33% of the issuer’s outstanding common stock as of the referenced date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:22 PM Accepted by SEC EDGAR 08/14/2026 - 04:15 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Inhibrx Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

45720N103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45720N103

1

Names of Reporting Persons

Schonfeld Strategic Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 781,678.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 781,678.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

781,678.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.33 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: The percentage of the issuer's common stock beneficially owned by the reporting person reflects 14,671,186 shares of common stock outstanding as of May 8, 2026, as set forth in the issuer's Quarterly Report on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on May 14, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Inhibrx Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 11025 N. Torrey Pines Road, Suite 140, La Jolla, California 92037
Item 2.
(a)	Name of person filing: Schonfeld Strategic Advisors LLC ("Schonfeld") is an investment adviser to several private funds. Schonfeld also engages third party sub-advisers to manage assets of its private funds as separately managed accounts (the "Schonfeld SMAs"). Accordingly, Schonfeld may be deemed to indirectly beneficially own securities owned by the Schonfeld SMAs. Each Schonfeld SMA is the record and direct beneficial owner of a portion of the securities covered by this statement. Schonfeld declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934 or any other purpose, the beneficial owner of any securities covered by this statement.
(b)	Address or principal business office or, if none, residence: 590 Madison Avenue, 23rd Floor, New York, New York 10022
(c)	Citizenship: Delaware limited liability company
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 45720N103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 781,678 shares
(b)	Percent of class: 5.33%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 781,678 shares
	(ii) Shared power to vote or to direct the vote: 0 shares
	(iii) Sole power to dispose or to direct the disposition of: 781,678 shares
	(iv) Shared power to dispose or to direct the disposition of: 0 shares
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The securities held by each of the Schonfeld SMAs as to which this statement is filed are owned of record by clients of Schonfeld. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Schonfeld Strategic Advisors LLC

Signature:	/s/ Hung Luc
Name/Title:	Hung Luc, Chief Compliance Officer
Date:	08/14/2026